List view / Grid view
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
n study 309, the pivotal phase III trial on which the indication approval was based, eribulin demonstrated a significant survival advantage in advanced liposarcoma; patients treated with eribulin compared to those treated with dacarbazine, a longstanding, established and internationally accepted treatment option, benefited from a median 7.2 month increase in…
8 July 2016 | By Victoria White, Digital Content Producer
Eisai has expressed concern that patients in England and Wales will have to wait three years to access Lenvatinib due to a ‘black hole’ in the CDF process...
12 May 2016 | By Victoria White, Digital Content Producer
Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue...
5 May 2016 | By Victoria White, Digital Content Producer
Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease...
5 April 2016 | By Victoria White
The European Medicines Agency’s CHMP has adopted a positive opinion for a licence extension for Eisai’s Halaven (eribulin)...
9 March 2016 | By Victoria White
From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer will have access to Eisai’s Lenvima (lenvatinib)...
26 February 2016 | By Victoria White
New licensed drugs that have been denied access since May 2015 will have to wait until at least July 2016 before they can be considered for the new Cancer Drug Fund...
17 February 2016 | By Victoria White
Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin...
11 February 2016 | By Victoria White
Eisai's Halaven (eribulin) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action...
29 January 2016 | By Victoria White
Halaven is the first and only single agent to demonstrate an overall survival benefit in a Phase III trial in patients with leiomyosarcoma or liposarcoma...
18 January 2016 | By Victoria White
The FDA has accepted for Priority Review Eisai’s supplemental New Drug Application for lenvatinib for the potential treatment of patients with renal cell carcinoma...
12 January 2016 | By Victoria White
Eisai has submitted the MAA to the EMA for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor targeted therapy...
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
